SUMO2/3 Antibody (SM23/496), Novus Biologicals™

Mouse Monoclonal Antibody

Product Code	Brand	Quantity
18108413	Novus Biologicals NBP2-34292-0.02MG	0.02 mg
18127722	Novus Biologicals NBP2-34292-0.1MG	0.1 mg

Description

SUMO2/3 Monoclonal specifically detects SUMO2/3 in Human samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Flow (Intracellular).

Specifications

• Antigen: SUMO2/3
• Dilution: Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 0.5-1ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate, Immunohistochemistry-Paraffin 0.5-1ug/ml, Immunohistochemistry-Frozen 0.5-1ug/ml
• Classification: Monoclonal
• Form: Purified
• Regulatory Status: RUO
• Formulation: PBS with 0.05% BSA. with 0.05% Sodium Azide
• Gene ID (Entrez): 6613
• Immunogen: Recombinant human SUMO2 protein
• Primary or Secondary: Primary
• Content And Storage: Store at 4C.

• Clone: SM23/496
• Applications: Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Immunohistochemistry (Paraffin)
• Conjugate: Unconjugated
• Host Species: Mouse
• Target Species: Human
• Gene Accession No.: P61956
• Gene Symbols: SUMO2
• Isotype: IgG1 κ
• Purification Method: Protein A purified
• Test Specificity: This MAb reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.